Statin myopathy: A review of recent progress

Current Opinion in Rheumatology

Volumn 22, Issue 6, 2010, Pages 644-650

  Mammen, Andrew L ^a   Amato, Anthony A ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

myopathy; necrotizing myopathy; statins; toxic myopathy

Indexed keywords

ADENOSINE MONOPHOSPHATE DEAMINASE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CARRIER PROTEIN; CHOLESTEROL; CORTICOSTEROID; CREATINE KINASE; CYTOCHROME P450 3A4; D 003; EZETIMIBE; FARNESYL DIPHOSPHATE; FIBRIC ACID DERIVATIVE; GERANYLGERANYL PYROPHOSPHATE; GLYCOGEN PHOSPHORYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MEVALONIC ACID; PHOSPHORYLASE KINASE; PRAVASTATIN; PROTEIN CPT2; RAB PROTEIN; RHO FACTOR; ROSUVASTATIN; SIMVASTATIN; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGE; APOPTOSIS; BODY MASS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE MUTATION; GENETIC CODE; GENETIC RISK; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOW DRUG DOSE; MUSCLE CRAMP; MUSCLE NECROSIS; MYALGIA; MYOPATHY; POLYMYOSITIS; PREDICTOR VARIABLE; PRENYLATION; PRIORITY JOURNAL; PROTEIN PRENYLATION; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; MUSCLE, SKELETAL; MUSCULAR DISEASES; SEVERITY OF ILLNESS INDEX;

EID: 77958033623     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32833f0fc7     Document Type: Review

References (52)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
2. Agency for Healthcare Research and Quality. Statistical brief #205. Trends in statins utilization and expenditure for the U.S. civilian noninstitutionalized population, 2000 and 2005. http://www.meps.ahrq.gov/ mepsweb/data-files/publications/st205/stat205.pdf. [Accessed 26 July 2010]
3. Christopher-Stine L Statin myopathy: an update. Curr Opin Rheumatol 2006; 18:647-653.
4. Baer AN, Wortmann RL Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 2007; 19:67-73.
5. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyo-lysis in patients treated with lipid-lowering drugs. JAMA 2004; 292:2585-2590.
6. De Sauvage Nolting PR, Buirma RJ, Hutten BA, et al. Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]). Am J Cardiol 2002; 90:181-184.
7. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 2005; 19:403-414.
8. Franc S, Dejager S, Bruckert E, et al. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 2003; 17:459-465.
9. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 29:743-759.
10. Garcia-Rodriguez LA, Masso-Gonzalez EL, Wallander MA, Johansson S.The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008; 17:943-952.
11. Garcia-Rodriguez LA, Gonzalez-Perez A, Stang MR, et al. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf 2008; 17:953-961.
12. Mosshammer D, Lorenz G, Meznaric S, et al. Statin use and its association with musculoskeletal symptoms: a cross-sectional study in primary care settings. Fam Pract 2009; 26:88-95.
13. Buettner C, Davis RB, Leveille SG, et al. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 2008; 23:1182-1186.
14. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 2007; 29:1761-1770.
15. Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statinclass from 1991-2006. PLoS One 2008; 3:e2522.
16. Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks ofrosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol 2008; 102:1654-1662.
17. MRC/BHF Heart Protection Study Collaborative Group, Armitage J, Bowman L, et al. Effects of simvastatin 40 mg daily on muscle and liver adverse effectsin a 5-year randomized placebo-controlled trial in 20,536 high-risk people.BMC Clin Pharmacol 2009; 9:6.
18. Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007; 29:253-260.
19. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
20. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
21. De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307-1316.
22. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445.
23. Backes JM, Howard PA, Ruisinger JF, Moriarty PM. Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother 2009; 43:2012-2020.
24. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
25. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287:3215-3222.
26. SEARCH Collaborative Group, LinkE, Parish S, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008;359:789-799.
27. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559.
28. Newman CB, Szarek M, Colhoun HM, et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res 2008; 5:177-183.
29. Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.Ann Pharmacother 2008; 42:341-346.
30. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80:565-581.
31. Rowan C, Brinker AD, Nourjah P, et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. PharmacoepidemiolDrug Saf 2009; 18:301-309.
32. Gonzalez FJ, Tukey RH. Drug metabolism. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006. Chapter 3.
33. Dorajoo R, Pereira BP, Yu Z, et al. Role of multidrug resistance-associated protein-1 transporter in statin-induced myopathy. Life Sci 2008; 82:823-830.
34. Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol 2008; 101:1606-1613.
35. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34:153-162.
36. Baker SK, Vladutiu GD, Peltier WL, et al. Metabolic myopathies discovered during investigations of statin myopathy. Can J Neurol Sci 2008; 35:94-97.
37. Echaniz-LagunaA,MohrM,TranchantC.Neuromuscularsymptoms and elevated creatine kinase after statin withdrawal. N Engl J Med 2010; 362:564-565.
38. Glueck CJ, Rawal B, Khan NA, et al. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism 2009; 58:233-238.
39. Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007; 17:194-200.
40. Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185-190.
41. Christopher-Stine L, Casciola Rosen L, Hong G, et al. A novel autoantibody recognizing 200 and 100kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010. [Epub ahead of print]
42. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010; 106:297-306.
43. Blanco-Colio LM, Villa A, Ortego M, et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosisof vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002; 161:17-26.
44. Johnson TE, Zhang X, Bleicher KB, et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol 2004; 200:237-250.
45. Yu JG, Sewright K, Hubal MJ, et al. Investigation of gene expression in C(2)C(12) myotubes following simvastatin application and mechanical strain. J Atheroscler Thromb 2009; 16:21-29.
46. Matzno S, Yasuda S, Juman S, et al. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol 2005; 57:1475-1484.
47. Sakamoto K, Honda T, Yokoya S, et al. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. FASEB J 2007; 21:4087-4094.
48. Itagaki M, Takaguri A, Kano S, et al. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J Pharmacol Sci 2009; 109:94-101.
49. Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117:3940-3951.
50. CaoP, Hanai J, Tanksale P, et al. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J 2009;23:2844-2854.
51. Nishiguchi T, Akiyoshi T, Anami S, et al. Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts. J Pharm Pharmacol 2009; 61:781-788.
52. Mullen PJ, Luscher B, Scharnagl H, et al. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences forstatin-induced myopathy. Biochem Pharmacol 2010; 79:1200-1209.